Pravin Dugel - 16 Jun 2026 Form 4 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
18 Jun 2026, 16:01:15 UTC
Prior SEC filing
28 May 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Todd Anderman, Attorney-in-Fact for Pravin Dugel

Key filing fact

Pravin Dugel filed Form 4 for OCULAR THERAPEUTIX, INC (OCUL) on 18 Jun 2026.

Key facts

  • This page summarizes Pravin Dugel's Form 4 filing for OCULAR THERAPEUTIX, INC (OCUL).
  • 2 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 18 Jun 2026, 16:01.

Change

  • Previous filing in this sequence was filed on 28 May 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001700917 Primary reporting owner

Dugel Pravin

Relationship
Executive Chairman, President and CEO, Director
Address
C/O OCULAR THERAPEUTIX, INC., 14 CROSBY DRIVE, 3RD FLOOR, BEDFORD
Signature
/s/ Todd Anderman, Attorney-in-Fact for Pravin Dugel
Signature date
18 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OCUL transaction

Common Stock

Gift

Transaction value
Shares
-50,092
Change %
-1.9%
Price
$0.000000*
Shares after
2,547,078
Date
16 Jun 2026
Ownership
Direct
Footnotes
F1
OCUL transaction

Common Stock

Gift

Transaction value
Shares
+50,092
Change %
Price
$0.000000*
Shares after
50,092
Date
16 Jun 2026
Ownership
By spouse
Footnotes
F1
OCUL holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
694,811
Date
16 Jun 2026
Ownership
By Pravin Dugel 2024 Irrevocable Trust
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On June 16, 2026, the reporting person transferred 50,092 shares to his spouse for no consideration.

SEC remarks

Executive Chairman, President and CEO

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .